Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders
Summary
The Cluster Health is under Pillar 2 of Horizon Europe. Its role is to advance knowledge and capabilities, improve understanding of health and diseases, develop innovative methodological and technological solutions to better manage health and diseases, as well as to design sustainable approaches for the digital transformation and delivery of integrated, person-centred and equitable health and care services.
Programme Name
Programme Description
Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Call
Detailed Call Description
Proposals should address all of the following aspects:
- Proposals should aim to validate biomarkers that can reliably confirm early stages of the human brain disorder and guide treatment/ intervention selection.
- Proposals should aim to provide evidence supporting the regulatory acceptance of the biomarkers.
- Exploitation of existing data, biobanks, registries and cohorts is expected, together with the generation of new key data.
- Inclusion of patients or patient organisations in the research is strongly encouraged, as to ensure that their views are considered.
- Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors should be taken into consideration in the study.
- To enable sharing of samples, quality data and advanced analytical and digital tools, consideration should be made for using infrastructures already developed at the European or national level.
- To enable the management of brain disorders, consideration should be made in demonstrating the gained cost efficiency.
Applicants invited to the second stage and envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.
Financing percentage by EU or other bodies / Level of Subsidy or Loan
100%
EU contribution per project: €6.00 and €8.00 million
Eligibility For Participation Notes
SME participation is encouraged.
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
Programme Category
EU Competitive ProgrammesTotal Budget
€25.00 millionThematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Associations
- Central Government
- Large Enterprises
- Legal Entities
- NGOs
- Non Profit Organisations
- Private Bodies
- Researchers/Research Centers/Institutions
- Semi-governmental organisations
- Small and Medium Enterprises (SMEs)
- State-owned Enterprises
Call Opening Date
26/04/2023Call Closing Date
19/09/2023National Contact Point(s)
Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia,
P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Persons:
George Christou
Scientific Officer
Email: gchristou@research.org.cy
Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Email: itheodorou@research.org.cy
(Publish Date: 07/04/2023-for internal use only)
EU Contact Point
European Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact